| scholarly article | Q13442814 |
| P50 | author | Willy Rozenbaum | Q2945169 |
| Pascale Trimoulet | Q47006535 | ||
| Christine Katlama | Q47006550 | ||
| Gwénaël Le Teuff | Q47008850 | ||
| P2093 | author name string | Yves Benhamou | |
| Herve Fleury | |||
| Isabelle Pellegrin | |||
| Aldo Trylesinski | |||
| Christophe Piketty | |||
| Renaud Urbinelli | |||
| TECOVIR Study Group | |||
| P2860 | cites work | Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 |
| Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients | Q28375088 | ||
| An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group | Q29614898 | ||
| Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection | Q30492398 | ||
| Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease | Q32086267 | ||
| Hepatitis B: an important public health issue | Q33947147 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment | Q35151034 | ||
| Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus | Q39451785 | ||
| Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine | Q39651695 | ||
| Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection | Q41604155 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. | Q42552411 | ||
| An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals | Q42690485 | ||
| Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus | Q43433204 | ||
| Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study | Q43599844 | ||
| Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation | Q43635554 | ||
| YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient | Q43772654 | ||
| Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. | Q43863563 | ||
| Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus | Q43906148 | ||
| Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study | Q44015302 | ||
| Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. | Q44042291 | ||
| The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state | Q44068644 | ||
| Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. | Q44226653 | ||
| Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation | Q44296008 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. | Q44355905 | ||
| Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase | Q44532948 | ||
| Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial | Q44579283 | ||
| Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus | Q44583350 | ||
| Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. | Q44709445 | ||
| Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. | Q44797474 | ||
| HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). | Q44933768 | ||
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 | ||
| Tenofovir therapy for lamivudine resistance following liver transplantation | Q45126707 | ||
| Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee | Q45741556 | ||
| Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee | Q45747996 | ||
| Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. | Q45750465 | ||
| Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group | Q45755649 | ||
| Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers | Q45762809 | ||
| Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine | Q45768670 | ||
| Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients | Q45784197 | ||
| Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. | Q46794204 | ||
| Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort | Q81600690 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| tenofovir | Q155954 | ||
| P304 | page(s) | 548-555 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients | |
| P478 | volume | 43 |
| Q46433832 | A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand |
| Q24187530 | Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection |
| Q39859839 | Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues |
| Q37527099 | Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines |
| Q33787531 | Antiviral therapy and resistance with hepatitis B virus infection |
| Q34223779 | Antiviral treatment of chronic hepatitis B virus (HBV) infections |
| Q34002160 | Chronic hepatitis B. |
| Q37149701 | Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients |
| Q26851240 | Current and future directions for treating hepatitis B virus infection |
| Q40096242 | Current antiviral therapies for chronic hepatitis B. |
| Q37278249 | Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B. |
| Q45398766 | Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection |
| Q34409132 | Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. |
| Q34657327 | Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis |
| Q94328073 | Emtricitabine for adults with lamivudine‐resistant chronic hepatitis B virus infection |
| Q37694907 | Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort |
| Q46243261 | Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. |
| Q33896067 | Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption |
| Q56786359 | From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™ |
| Q44922847 | HIV coinfection with hepatitis C and hepatitis B. |
| Q58376622 | Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV |
| Q26822862 | Hepatitis B and human immunodeficiency virus co-infection |
| Q44082617 | Hepatitis B in HIV: available treatment options and approach to therapy |
| Q46188049 | Hepatitis B in patients with HIV infection |
| Q45398019 | Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004. |
| Q37109700 | Hepatitis B viruses: reverse transcription a different way. |
| Q37632321 | Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy |
| Q34364620 | Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand |
| Q42795326 | Long-term therapy for chronic hepatitis B in HIV co-infected patients |
| Q43823859 | Management of HCV-HIV and HBV-HIV coinfected patients |
| Q37772508 | Management of HIV and hepatitis virus coinfection |
| Q36849343 | Management of chronic hepatitis B: consensus guidelines |
| Q37176668 | Management of hepatitis B virus co-infection on and off antiretroviral therapy |
| Q36881140 | Molecular testing in the diagnosis and management of chronic hepatitis B |
| Q35026531 | New approaches in the management of chronic hepatitis B: role of tenofovir. |
| Q46188062 | Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B |
| Q37432098 | Pathobiology of HBV mutants and clinical impact for treatment monitoring. |
| Q36956933 | Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus |
| Q34024622 | Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil |
| Q37424372 | Prevention and management of drug resistance for antihepatitis B treatment |
| Q33968358 | Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. |
| Q36699205 | Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort |
| Q38088408 | Role of molecular diagnostics in the management of viral hepatitis B. |
| Q58098975 | Role of tenofovir in the treatment of chronic HBV infection |
| Q28972486 | Safety and efficacy of telbivudine for the treatment of chronic hepatitis B |
| Q37462562 | Side effects of long-term oral antiviral therapy for hepatitis B. |
| Q91908886 | Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses |
| Q41435482 | Tenofovir and its potential in the treatment of hepatitis B virus. |
| Q44377239 | Tenofovir disoproxil fumarate: role in hepatitis B treatment |
| Q37605886 | Tenofovir for the treatment of hepatitis B virus |
| Q83367686 | Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure |
| Q46458706 | The patient with uncontrolled chronic hepatitis B |
| Q38071400 | Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues |
| Q37124882 | Treatment of chronic hepatitis B and the implications of viral resistance to therapy |
| Q46458724 | Treatment of chronic hepatitis B in HIV co-infected patients |
| Q42843222 | Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? |
| Q37886158 | Treatment of special populations with chronic hepatitis B infection |
| Q36612848 | Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria. |
| Q37287635 | Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy |
| Q34213161 | Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort |
| Q37762108 | Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy |
Search more.